Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$3.42
+5.2%
$2.33
$0.80
$3.49
$898.22M0.882.99 million shs7.16 million shs
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
$3.51
+4.8%
$2.86
$2.01
$5.64
$233.51M1.611.14 million shs848,522 shs
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
$41.20
+3.5%
$35.71
$26.70
$91.83
$839.20M2.65385,656 shs243,916 shs
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
$4.65
-7.9%
$4.61
$2.03
$6.07
$727.19M1.11.96 million shs5.10 million shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
+5.23%+17.12%+39.59%+84.37%+200.00%
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
+4.78%+13.23%+24.47%-17.80%+10.73%
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
+3.47%+14.13%+2.39%+8.85%-12.43%
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
-7.92%-3.73%-1.27%+23.34%+89.80%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
4.1321 of 5 stars
4.61.00.04.02.90.00.6
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
1.7544 of 5 stars
3.50.00.00.04.00.00.6
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
2.8216 of 5 stars
4.42.00.00.02.71.70.0
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
4.404 of 5 stars
4.41.00.04.23.41.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
3.20
Buy$6.6393.71% Upside
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
3.00
Buy$12.00241.88% Upside
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
2.80
Moderate Buy$109.90166.75% Upside
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
2.83
Moderate Buy$6.2534.41% Upside

Current Analyst Ratings Breakdown

Latest CRDF, XERS, PRAX, and AKBA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/2/2025
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$97.00
5/9/2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$17.00 ➝ $18.00
5/9/2025
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$6.00 ➝ $7.00
5/7/2025
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$80.00
5/5/2025
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetUnderperform ➝ Underperform$26.00 ➝ $28.00
5/5/2025
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
5/1/2025
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$105.00 ➝ $105.00
4/28/2025
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/28/2025
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$7.00
4/8/2025
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$85.00 ➝ $85.00
4/4/2025
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.50 ➝ $7.50
(Data available from 6/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$184.91M4.86N/AN/A($0.16) per share-21.38
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
$587K397.80N/AN/A$1.56 per share2.25
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
$8.12M103.32N/AN/A$7.92 per share5.20
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
$222.55M3.27N/AN/A($0.05) per share-93.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
-$51.92M-$0.21N/AN/AN/A-27.07%N/A-20.57%8/7/2025 (Estimated)
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
-$41.44M-$0.92N/AN/AN/A-6,238.17%-73.97%-60.40%8/14/2025 (Estimated)
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
-$123.28M-$10.72N/AN/AN/A-9,409.22%-54.86%-50.52%8/12/2025 (Estimated)
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
-$62.26M-$0.30N/AN/AN/A-33.69%N/A-17.38%8/14/2025 (Estimated)

Latest CRDF, XERS, PRAX, and AKBA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
-$0.03$0.03+$0.06$0.03$44.88 million$57.34 million
5/8/2025Q1 2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
-$0.19-$0.20-$0.01-$0.20$0.09 million$0.11 million
5/8/2025Q1 2025
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
-$0.07-$0.06+$0.01-$0.06$57.61 million$57.80 million
5/2/2025Q1 2025
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
-$3.20-$3.29-$0.09-$3.29$0.20 millionN/A
3/13/2025Q4 2024
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
-$0.05-$0.10-$0.05-$0.10$37.36 million$46.50 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
N/AN/AN/AN/AN/A
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
N/AN/AN/AN/AN/A
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
N/AN/AN/AN/AN/A
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
N/A
1.52
1.21
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
N/A
4.74
4.74
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
N/A
10.96
10.96
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
N/A
1.79
1.29

Institutional Ownership

CompanyInstitutional Ownership
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
33.92%
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
16.29%
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
67.84%
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
42.75%
CompanyEmployeesShares OutstandingFree FloatOptionable
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
430262.64 million209.24 millionOptionable
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
2066.53 million47.15 millionOptionable
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
11020.37 million18.14 millionOptionable
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
290156.39 million142.28 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Akebia Therapeutics stock logo

Akebia Therapeutics NASDAQ:AKBA

$3.42 +0.17 (+5.23%)
Closing price 06/3/2025 04:00 PM Eastern
Extended Trading
$3.44 +0.02 (+0.44%)
As of 05:50 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Cardiff Oncology stock logo

Cardiff Oncology NASDAQ:CRDF

$3.51 +0.16 (+4.78%)
Closing price 06/3/2025 04:00 PM Eastern
Extended Trading
$3.73 +0.22 (+6.24%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Praxis Precision Medicines stock logo

Praxis Precision Medicines NASDAQ:PRAX

$41.20 +1.38 (+3.47%)
Closing price 06/3/2025 04:00 PM Eastern
Extended Trading
$41.18 -0.03 (-0.06%)
As of 06/3/2025 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Xeris Biopharma stock logo

Xeris Biopharma NASDAQ:XERS

$4.65 -0.40 (-7.92%)
Closing price 06/3/2025 04:00 PM Eastern
Extended Trading
$4.68 +0.03 (+0.67%)
As of 06/3/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.